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1Pulmonary arterial hypertension (PAH) is a debilitating condition that results in dyspnea and fatigue, impaired 
exercise capacity, and reduced survival.1 Modest improve-
ments in 6-minute walk distance (6MWD) can be achieved 
with endothelial-receptor antagonists, phosphodiesterase 
type-5 inhibitors, and prostacyclin analogs,1–3 although the 
extent of improvement varies according to the cause of PAH,2 
and the effects on morbidity and mortality are less certain.4 
Combination therapy with multiple drugs targeting different 
pathways has been recommended, increasing the likelihood 
of side effects.5,6
See Editor’s Perspective by Leopold
Sympathetic overactivation has been reported, and the 
effect of β-blockers in PAH patients has been assessed.1 
Pulmonary artery nerve denervation could completely resolve 
the increase in pulmonary arterial pressure (PAP) induced by 
an expandable device in the left lobar artery.7,8 Furthermore, 
we reported short-term clinical results of pulmonary artery 
denervation (PADN) without the use of PAH target drugs, 
which was associated with significant reductions in PAP and 
improvement in 6MWD at the 3-month follow-up in patients 
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with idiopathic PAH (IPAH) who were unresponsive to medi-
cation.9 Since this report, questions have arisen on the pro-
cedural safety, long-term results, and potential for aneurysm 
and thrombus formation.9 In addition, the effects of PADN 
on other causes of PAH are unknown. Therefore, we sought 
to further investigate the hemodynamic, functional, and 
clinical responses to PADN (stand-alone therapy) in patients 
with PAH of different causes in this phase II report from the 
PADN-1 study.
Methods
PADN-I Registry and Patient Population
PADN-I phase I began in March 2012 and ended in May 20129 and 
was a first-in-man study that tested the safety and efficacy of PADN 
in 13 patients with IPAH who were unresponsive to standard medica-
tion. PADN-I phase II began in April 2012 and ended in April 2014, 
during which time PADN was performed in 66 consecutive patients 
with PAH.
Inclusion and Exclusion Criteria
Patients with a resting mean PAP (mPAP) ≥25 mm Hg, as measured 
by right heart catheterization, were included, although they were re-
ceiving PAH expert–based standard medical treatment. In patients 
with pulmonary hypertension (PH) caused by left ventricular (LV) 
dysfunction, an additional requirement was pulmonary vascular re-
sistance (PVR) ≥3 Wood units. An adenosine vasodilator test8 was 
performed during right heart catheterization in all patients. Exclusion 
criteria included active infection, cancer, toxin- or anorexia-induced 
PH, portal hypertension, chronic thromboembolic PH without surgi-
cal treatment, intolerance to the PADN procedure (caused by the use 
of an 8-F-long sheath that occludes blood flow in the orifice of the 
tricuspid and pulmonary valves, resulting in severe dyspnea), and in-
ability to provide consent.
This study was approved by the Institutional Review Board and 
Ethics Committee of the Nanjing First Hospital (Nanjing, China), and 
all patients provided written inform consent.
Right Heart Catheterization
Resting right atrial (RA) pressure, right ventricular (RV) pressure, 
PAP, pulmonary artery occlusion pressure (PAOP), and thermodilu-
tion cardiac output were obtained with a 7-F flow-directed Swan-Ganz 
catheter. PVR ([mPAP−PAOP]/cardiac output) and transpulmonary 
gradient (mPAP−PAOP) were then derived. All measurements were 
taken at end expiration. If the PAOP measurement was unreliable,1,3,10 
the LV end-diastolic pressure was used rather than the PAOP. Blood 
samples from the RA, RV, and PA were obtained, and if the oxygen 
saturation measurements varied by >7% between chambers, further 
sampling was performed to identify the location of the left-to-right 
shunt.
PADN Procedure
PA ablation was performed using a dedicated 7-F temperature-sens-
ing ablation catheter. The details of the device and the PADN proce-
dure have been previously described.7,8 Briefly, PADN was thereafter 
performed only in the periconjunctional area between the distal main 
trunk and the ostial left branch (points A, B, and C in Figure 1).
The following ablation parameters were programmed at each 
point: temperature ≥45°C, energy ≤20 W, and time 120 s (for point 
C) or 240 s (for points A and B). The procedure was interrupted for 
10 s if the patient reported severe chest pain. Electrocardiography and 
hemodynamic function were monitored and recorded continuously 
throughout the procedure.
Periprocedural Medication
A 5000-U heparin bolus was administered after the insertion of the 
venous sheath. Additional 2000- to 3000-U heparin boluses were 
administered if the procedural time was >1 hour. After the proce-
dure, oral warfarin was prescribed and adjusted to an international 
normalized ratio of 1.5 to 2.5 for all patients. Aspirin (100 mg per 
day) and clopidogrel (75 mg per day) were indefinitely prescribed in 
the presence of contraindications for warfarin. Immediately after the 
PADN procedure, all target drugs (endothelial-receptor antagonists, 
phosphodiesterase type-5 inhibitors, and prostacyclin analogs) were 
discontinued. Diuretics were prescribed at a dosage less than or equal 
to that at baseline. Oxygen therapy was used according to patients’ 
symptoms, as assessed by a physician.
Assessment of Functional Capacity
Functional capacity was determined using a standard 6MWD pro-
tocol1,4 before PADN and at 1 week, 1 month, 2 months, 3 months, 
6 months, and 1 year after the procedure. Dyspnea was assessed by 
using the Borg scale.11 The World Health Organization (WHO) clas-
sification of dyspnea at rest and during exercise was recorded by a 
physician blinded to the study design.1 Baseline blood samples were 
obtained to measure N-terminal pro–brain natriuretic peptide levels 
before each exercise test.
Echocardiographic Measurements
Transthoracic echocardiography (Vivid 7, General Electric Co, 
Easton Turnpike, CT) was performed immediately after the proce-
dure and at 24 hours, 1 week, 1 month, 2 months, 3 months, 6 months, 
and 1 year and was analyzed at the Nanjing Medical University 
Echocardiographic Laboratory. Digital echocardiographic data that 
contained a minimum of 3 consecutive beats (or 5 beats in cases of 
atrial fibrillation) were acquired and stored. RV systolic pressure was 
set equal to systolic PAP (sPAP) in the absence of pulmonary steno-
sis. sPAP was calculated as the sum of RA pressure and the RV to RA 
pressure gradient during systole. RA pressure was estimated based on 
the echocardiographic features of the inferior vena cava and assigned 
a standard value. The RV to RA pressure gradient was calculated as 
WHAT IS KNOWN
•	Pulmonary arterial hypertension is characterized 
by reduced survival from the time of diagnosis, and 
there are a limited number of drugs that have thera-
peutic efficacy in the disease.
•	Overactivation of the sympathetic nervous system 
and its direct effects on pulmonary artery vasocon-
striction play a critical role in the pathogenesis of 
pulmonary arterial hypertension.
•	A proof-of-concept study testing pulmonary ar-
tery denervation was completed in a limited num-
ber of patients with low-risk pulmonary arterial 
hypertension.
WHAT THE STUDY ADDS
•	The pulmonary artery denervation procedure was 
safely and feasibly performed in 66 consecu-
tive patients with different forms of pulmonary 
hypertension.
•	A randomized study with a larger patient population 
is required to determine whether there is therapeutic 
efficacy of pulmonary artery denervation in patients 
with pulmonary hypertension.
3  Chen et al  Outcomes After PADN for PH
4vt2 using the modified Bernoulli equation, where vt is the velocity of 
the tricuspid regurgitation jet in m/s. The mPAP was estimated ac-
cording to the velocity of the pulmonary regurgitation jet in m/s. The 
tricuspid excursion index is defined as (A−B)/B, where A is the time 
interval between the end and the onset of tricuspid annular diastolic 
velocity and B is the duration of tricuspid annular systolic velocity (or 
the RV ejection time).12
Follow-Up
Patients were monitored in the critical care unit for at least 24 hours 
post procedure. Hemodynamic measurements, 6MWD, and echo-
cardiographic measurements were repeated at 24 hours, 1 month, 2 
months, 3 months, 6 months, and 12 months. Clinical follow-up was 
extended to 1 year. Magnetic resonance imaging and computed tomo-
graphic imaging of the pulmonary artery were performed before the 
PADN procedure and at 6 months.
Study End Points and Definitions
The primary end points were changes in hemodynamic, functional, 
and clinical responses within the 1-year follow-up. PAH-related clini-
cal events were defined as those caused by worsening of PAH, initia-
tion of treatment with intravenous or subcutaneous prostanoids, lung 
transplantation, atrial septostomy, or all-cause mortality. Worsening 
of PAH was defined as the occurrence of all 3 of the following: ≥15% 
decrease in 6MWD from baseline, confirmed by a second 6MWD 
performed on a different day within 14 days; worsening PAH symp-
toms; and the need for additional treatment for PAH. Worsening PAH 
symptoms were defined as a change from baseline to a higher WHO 
functional class (or no change in WHO functional class IV from that at 
baseline) plus the appearance or worsening signs of right heart failure 
not responsive to oral diuretic therapy. An independent clinical event 
committee adjudicated all deaths and reported events with respect to 
their relationship with PAH. Additional secondary end points included 
changes in 6MWD, WHO functional class, N-terminal pro–brain na-
triuretic peptide levels, PAH-related or all-cause mortality, echocar-
diographic measurements, and rehospitalization rates for PAH in the 
long term. The prespecified definition of PADN procedural hemody-
namic success was reduction in mPAP immediately after PADN by 
≥10, without the occurrence of any intraprocedural complications.
Statistical Analysis
Continuous variables are expressed as mean±SD. Normality was ex-
amined using the Kolmogorov–Smirnov and Shapiro–Wilk tests. Data 
having unequal variances at different times were transferred to log 
data. Differences in continuous variables between 2 different timing 
points (baseline versus 6 months or 6 months versus 1 year) were ana-
lyzed with paired t tests. Categorical variables between group I, group 
II, and chronic thromboembolic PH groups or between 2 different 
timing points were compared by using Fisher exact or McNemar test, 
as appropriate. Event-free survival rate at 1 year was estimated by us-
ing the Kaplan–Meier method. Statistical significance was defined as 
a 2-sided P value of <0.05. All analyses were performed with SPSS 
16.0 (SPSS Institute Inc, Chicago, IL).
Data and Materials Availability
All raw data are available on request. PADN devices are available 
from Pulmo Co. Ltd (Wuxi, China).
Results
Patient Population
In all, 70 patients with qualifying PAH/PH were screened dur-
ing the study period. Four patients were excluded: 2 patients 
with IPAH could not lie flat for 20 minutes, 1 with WHO 
group II PAH died in the ward after consent while waiting for 
the procedure, and 1 with WHO group IV PAH died of tempo-
rary pacing catheter-induced RV perforation before the PADN 
procedure. Thus, the study population consisted of 66 patients 
in whom PADN was attempted.
Cause and Baseline Characteristics
Among the 66 patients, 39 (59.1%) had WHO group I PAH 
(IPAH in 20 patients; 11 had PH secondary to connective tis-
sue disorders; and 8 had PH secondary to congenital heart 
disease after surgical repair), 18 (27.3%) had group II PAH 
(PH secondary to LV dysfunction), and 9 (13.6%) had chronic 
thromboembolic PH after surgery. Of the 11 connective tis-
sue disorders patients, 7 had systemic lupus erythematosus, 
2 had mixed connective tissue disease, and 2 had primary 
Sjogren syndrome; of the 8 congenital heart disease after sur-
gical repair patients, 5 had an atrial septal defect and 3 had 
patent ductus arteriosus. Of the patients with group II PAH, 
15 had a previous myocardial infarction, and 3 had dilated 
cardiomyopathy.
Baseline clinical characteristics are shown in Table 1. The 
average time from diagnosis of PAH to the PADN procedure 
was 3.8 years. A combination of drugs was required for 89.1% 
of patients. Most patients (90.9%) had WHO function classes 
II and III. In all, 55 patients (83.3%) were administered oxygen 
therapy. In all, 37 (56.1%) had pericardial effusion (Table 2).
Figure 1. Pulmonary arterial angiography, position of electrodes, and pulmonary artery denervation (PADN) procedure. (I) Anterior-pos-
terior and cranial (200) view of the pulmonary arterial angiograph. (II) The red line represents the lateral wall of the main pulmonary artery 
(MPA), the blue line represents the anterior wall of the left pulmonary artery (LPA), and the point where the 2 lines intersect is point A; the 
intersection of the yellow (posterior wall of the LPA) and red lines is point B, which is 1 to 2 mm posterior to point A; the green line starts 
from the inferior wall of the right pulmonary artery (RPA) and ends at point A, and point C localizes at this level and 1 to 2 mm anterior to 
point A. (III) A pulmonary artery denervation catheter with 10 electrodes is positioned at the distal MPA, with electrodes A, B, and C at 
points A, B, and C, respectively.
4  Chen et al  Outcomes After PADN for PH
Procedural Outcomes and Safety
The median (interquartile range) duration of ablation at 
2.8±0.3 sites during the PADN procedure was 22 (11–38) min-
utes. During the procedure, 47 patients (71.2%) complained 
of chest pain (including 3 patients [4.5%] with severe chest 
pain), and 15 patients (22.7%) complained of a vague chest 
discomfort. All patients tolerated these symptoms without the 
need for additional sedative or analgesic agents. One patient 
developed sinus bradycardia from 88 to 43 bpm during the 
first ablation; the patient recovered after 3 minutes. A second 
PADN was attempted in 3 patients 2 to 4 days after the first 
attempt, during which patients were intolerable to dyspnea.
Hemodynamic Responses to the PADN Procedure
As shown in Figure 2A, the mean absolute reduction in 
mPAP was −5 mm Hg (12.8±9.2% reduction) immediately 
post PADN procedure and −6.6 mm Hg (12.2±2.6%) at 24 
hours after PADN. Hemodynamic success was achieved in 62 
patients (93.9%). On the basis of univariable analysis, the pre-
dictors of hemodynamic failure were sPAP (P=0.022), mPAP 
(P=0.011), and pericardial effusion (P=0.036).
During the 6-month follow-up, there were significant 
reductions in sPAP, mPAP, diastolic PAP, RA pressure, and 
RV systolic pressure; and increment in cardiac output (all 
P<0.05) measured by either echocardiography (Table 2) or 
right heart catheterization (Table 3) all of which led to a 
significant decrease in PVR (Table 3; Figure 2B). However, 
there were no further improvements in values at 1-year 
follow-up compared with values at the 6-month follow-up 
(Table 3).
Exercise Capacity, Functional Class, and Cardiac 
Function
The 6MWD increased by a mean of 94±73 m (Figure 2C). The 
N-terminal pro–brain natriuretic peptide value decreased from 
2229±2922 ng/mL at baseline to 917±947 ng/mL at the 1-year 
follow-up (P<0.001; Figure 2D; Table 4). During the 6-month 
follow-up, the WHO functional class improved in 42 patients 
(63.6%); among 56 patients who survived for 1 year, the mean 
paired WHO class was 2.7±0.6 at baseline and 1.9±0.7 at the 
last follow-up (P<0.001).
Table 2 shows the average reduction in RA (the long axis 
but not the short axis) and RV diameter at the 6-month fol-
low-up, and these were 1.98 and 2.21 mm, respectively, with 
simultaneously significant absorption of pericardial effusion 
and reduction of tricuspid excursion index. Notably, left 
ventricular end-diastolic dimension and LV ejection fraction 
increased from 45.8±13.1 mm and 61.6±13.2% at baseline 
to 47.4±12.9 mm (P=0.024) and 63.9±13.2% (P=0.001) at 
6-month follow-up, respectively. In contrast, left ventricular 
Table 1. Baseline Clinical Characteristics of All Patients
Total (n=66) Group I (n = 39) Group II (n = 18) CTEPH (n = 9) P Value
Age, y 52±16 44±15 66±11 56±7 0.001
Men, n (%) 27 (41) 10 (26) 12 (67) 5 (56) 0.009
Heart rate, bpm 78±13 80±14 74±13 74±15 0.025
Time from diagnosis of PAH to PADN, y 3.8±5.2 3.8±5.3 3.9±6.7 3.7±4.6 0.901
Presentation, n (%)
  Syncope 15 (22.7) 11 (28.2) 1 (5.6) 2 (22.2) 0.103
  Fatigue 61 (92.4) 37 (94.9) 16 (88.9) 8 (88.9) 0.665
  Chest pain 12 (18.2) 4 (10.3) 5 (27.8) 3 (33.3) 0.126
  Dyspnea 64 (96.0) 39 (100.0) 17 (94.4) 8 (88.9) 0.165
Medication, n (%)
  Calcium-channel blocker 7 (10.6) 4 (10.3) 2 (11.1) 1 (11.1) 0.994
  Sildenafil 3 (4.5) 2 (5.1) 2 (11.1) 1 (11.1) 0.342
  Bosentan 8 (12.1) 7 (17.9) 0 (0) 1 (11.1) 0.155
  Prostaglandin 44 (66.7) 22 (56.4) 16 (88.9) 6 (66.6) 0.054
  Diuretics 46 (69.7) 22 (56.4) 17 (94.4) 7 (77.8) 0.013
  Digoxin 21 (31.8) 6 (15.4) 14 (77.8) 1 (11.1) <0.001
  Combination of drugs 59 (89.1) 37 (94.9) 16 (88.9) 6 (66.7) 0.075
  Oxygen 55 (83.3) 35 (89.7) 15 (88.3) 5 (55.6) 0.147
NT-pro BNP, ng/mL 2221±2881 1701±278 3489±1074 1937±664 0.035
6MWD, m 358±118 344±118 397±129 339±81 0.105
Functional class, n (%) 0.141
  I 2 (3.0) 1 (2.6) 1 (5.6) 0
  II 21 (31.8) 13 (33.3) 8 (44.4) 0
  III 39 (59.1) 23 (59.0) 7 (38.9) 9 (100.0)
  IV 4 (6.0) 2 (5.1) 2 (11.1) 0
6MWD indicates 6-minute walk distance; BNP, brain natriuretic peptide; CTEPH, chronic thrombolytic pulmonary hypertension; NT, N-terminal; 
PADN, pulmonary artery denervation; and PAH, pulmonary arterial hypertension.
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end-systolic dimension decreased from 31.7±14.4 mm 
at baseline to 29.4±14.5 mm at the 6-month follow-up 
(P=0.041). Similar to changes in hemodynamics, no further 
improvements in right heat size and cardiac function were 
noted at the 1-year follow-up compared with values at the 
6-month follow-up.
During the follow-up, PAH target drugs were prescribed 
in 9 patients (3 in group I, 5 in group II, and 1 chronic 
Table 2. Echocardiographic Measurements at Baseline and 1 Year After PADN
Baseline (n=66) 6 m (n=65) 1 y (n=56) P Value*
Left atrial diameter-s, mm 40.9±8.8 41.5±9.2 41.8±8.9 0.75
Left ventricular diameter-d, mm 45.8±13.1 47.4±12.9 47.2±11.2 0.024
Left ventricular diameter-s, mm 31.7±14.4 29.4±14.5 29.6±14.1 0.041
Left ventricular EF, % 61.6±13.2 63.9±13.2 64.8±12.6 0.001
Systolic PAP, mm Hg 93.3±30.9 80.6±25.4 79.1±22.7 <0.001
Mean PAP, mm Hg 41.4±12.8 36.1±12.8 35.7±12.6 <0.001
Right atrial pressure, mm Hg 11.2±2.7 8.9±2.5 8.2±2.4 <0.001
Systolic RVP, mm Hg 91.5±30.6 81.2±26.3 78.3±22.4 <0.001
Right atrial diameter, mm
  Long axis 58.5±11.2 55.8±12.1 56.4±10.7 <0.001
  Short axis 49.4±10.5 48.7±11.4 49.0±10.0 0.39
Right ventricular diameter, mm 47.5±10.6 45.2±10.3 45.0±10.1 0.046
Pericardial effusion, mm† 3.4±4.5 1.5±1.7 1.2±1.6 0.039
  Any, n (%) 37 (56.1) 24 (43.5) 22 (40.0) 0.17
Tei, % 0.63±0.15 0.42±0.17 0.39±0.11 <0.001
EF indicates ejection fraction; PAP, pulmonary arterial pressure; RVP, right ventricular pressure; and Tei, 
tricuspid excursion index.
*Indicates the comparison of baseline vs 6 month; all variables were nonsignificantly different between 6 
mo vs 1 y.
†Data were transferred to log data for analysis.
Figure 2. Dynamic changes in mean pulmonary arterial pressure (A), pulmonary vessel resistance (B), 6-minute walk distance (C), and 
N-terminal pro–brain natriuretic peptide (NT pro-BNP; D, after transferred to log data) levels. All variables improved significantly at the 
6-month follow-up, without any additional significant change between the 6-month and the 1-year follow-up.
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thromboembolic PH) according to patients’ expectation because 
of a slight nonsignificant increase in PVR after 6 months, and 
these drugs were then stopped after an average of 2.6 months 
since prescription.
Procedural Safety, Morbidity, and Mortality
There were no PA perforations or other major cardiac or vas-
cular complications. On the magnetic resonance imaging and 
computed tomography at the 6-month follow-up in 58 patients, 
no signs of thrombus or aneurysm formation were observed.
The 1-month and 6-month PAH-related event rates were 
1.5% and 7.6%, respectively (Table 4). The median (interquar-
tile range) follow-up was 652 (279–1130) days. As shown in 
Figure 3, PAH-related adverse events occurred in 10 patients 
during the 1-year follow-up (1-year 15.2% Kaplan–Meier esti-
mated rate; Figure 3; Table 4). All-cause mortality occurred in 
8 patients (1-year 12.1% Kaplan–Meier estimated rate) during 
the follow-up. Of the 8 deaths, 7 patients with group I PAH died 
after PADN: 1 with IPAH died of septic shock at 87 days, 2 with 
IPAH died of RV failure at 378 or 406 days, 1 with connective 
tissue disorders died of cerebral hemorrhage at 7 days, 2 with 
connective tissue disorders died of RV failure at 392 or 437 
days, and 1 with congenital heart disease after surgical repair 
died of a traffic accident at 206 days. One patient with group II 
PAH died of RV failure at 433 days after the indexed procedure.
Univariable analysis showed that patients without an 
event at the 1-year follow-up had a slower resting heart rate 
(P=0.043), lower PAP values (based on either right heart 
catheterization or echocardiography), less pericardial effu-
sion (P=0.010), and higher 6MWD values (P=0.041) than the 
patients with events at the 1-year follow-up.
Discussion
To the best of our knowledge, this is the first study to report 
hemodynamic, functional, and clinical responses to PADN in 
patients with PAH of different causes. The major finding is 
that the PADN procedure was associated with favorable 1-year 
outcomes, as evidenced by improvements in WHO functional 
class, 6MWD, N-terminal pro–brain natriuretic peptide levels, 
and a low rate of PAH-related events.
Table 3. Right Heart Catheterization Measurements at Baseline and 6-Month 
and 1-Year Follow-Up
Baseline (n=66) 6 mo (n=65) 1 y (n=56) P Value*
Systolic PAP, mm Hg 86.6±28.9 71.6±25.8 70.1±27.6 <0.001
Mean PAP, mm Hg 53.1±19.1 44.8±16.4 44.6±17.6 <0.001
Diastolic PAP, mm Hg 34.8±15.1 29.9±14.2 28.4±13.9 <0.001
Right atrial pressure, mm Hg 12.4±7.3 10.6±5.8 10.3±5.4 0.005
Systolic RVP, mm Hg 85.1±28.4 75.3±29.7 72.9±29.7 <0.001
PAOP, mm Hg† 14.7±11.7 12.4±5.3 11.8±5.2 0.075
Cardiac output, L/min 3.3±1.2 4.0±1.1 4.1±1.0 <0.001
PVR, Wood units 13.2±6.9 8.4±5.8 8.3±6.6 <0.001
PAOP indicates pulmonary occlusion pressure; PAP, pulmonary arterial pressure; PVR, pulmonary 
vessel resistance; and RVP, right ventricular pressure.
*Indicated the comparison of baseline vs 6 mo; all variables were nonsignificantly different 
between 6 mo vs 1 y.
†Data were transferred to log data for analysis.
Table 4. Clinical Outcomes at the 1-Year Follow-Up in 66 Patients
1 mo 6 mo 12 mo
PAH-related events, n (%) 1 (1.5) 5 (7.6) 10 (15)
  Death 0 1 (5.6) 6 (9)
  Atrial septostomy 0 0 0
  Wait listed for lung transplant 0 0 2 (3)
  Requiring IV or SQ drugs 0 2 (3) 6 (9)
  Worsening of PAH 1 (1.5) 2 (3) 6 (9)
   15% decrease in 6MWD 2 (3) 3 (16.7) 8 (12)
   Worsening of symptoms 1 (1.5) 2 (3) 6 (9)
   Additional treatments 1 (1.5) 3 (16.7) 14 (21)
All-cause mortality 1 (1.5) 1 (5.6) 8 (12)
Rehospitalization 1 (1.5) 4 (22) 13 (19.7)
∆NT pro-BNP, ng/mL −673±896* −1189±2551 −1291±2662
∆ indicates 6-mo minus baseline; 6MWD, 6-minute walk distance; BNP, brain natriuretic 
peptide; IQR, interquartile range; IV, intravenous; NT, N terminal; and SQ, subcutaneous.
*Compared with 6 mo (P=0.029) and 1 y (P=0.005) after transferred to log data.
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Neurohumoral activation in PAH is evidenced by 
increased circulating catecholamine levels,13 abnormally 
high muscle sympathetic nerve activity,13,14 and impaired 
heart rate variability,13–15 which forms the theoretical basis 
of using β-blockers16 and PADN7,8 to treat PAH. As a result, 
the success of PAH therapies has been measured in terms of 
reduction in PAP and PVR. The hemodynamic response to 
medication using target drugs within 4 weeks to 6 months 
varies widely,2,17,18 with a mean reduction in mPAP to <3 
mm Hg. Compared with renal denervation, which did not 
result in immediate reduction in blood pressure,19 PADN 
results in an immediate reduction in PAP; the current results 
confirm our previous finding.7,9 Furthermore, we found that 
post-PADN reductions in sPAP (−8 mm Hg) and mPAP (−5 
mm Hg) were sustained throughout the follow-up period. 
This implies that PADN might be beneficial for a wide variety 
of PAH causes. Notably, we also found no further reduction 
in PAP or further improvement in 6MWD after the 6-month 
follow-up, which might indicate that significant improve-
ment in PA remodeling20 was achieved within 6 months after 
PADN treatment; however, this is not supported by extensive 
evidence. Repeated PADN combined with target drugs is pos-
tulated to provide more beneficial in patients with PAH.
The predictors of nonresponsiveness after medical treat-
ment in patients with PAH have been poorly characterized. In 
our study, the nonresponder rate was 6.1% (n=4). Furthermore, 
we found that sPAP, mPAP, and pericardial effusion correlated 
with PADN procedure failure. An excessive increase in PAP 
reflects the severity of PAH.1 Pericardial fluid accumulation 
results in diastolic dysfunction because of impaired relax-
ation.15 In the 4 nonresponders, a gradual reduction in PAP 
was noted after the absorption of pericardial effusion for 3 
months, suggesting an important role of pericardial effu-
sion in treating PAH.7,15 However, given the small number 
of patients who did not respond to PADN in this study, addi-
tional data are required to determine the correlation of proce-
dural outcomes with this novel approach to PAH.
Improvement in 6MWD has been used as the primary end 
point in most of the previous studies on PAH therapeutics, and 
a 15% reduction in 6MWD is one criterion of PAH worsen-
ing.1–6 Previous studies have reported a mean increase of +34 
m in the 6MWD at a median 14.5-week follow-up,1–6,21 which 
is lower than that in our study (+94 m). In addition to improve-
ments in hemodynamic function, WHO functional class, and 
cardiac function, our results demonstrated that PADN resulted 
in improvement in PA remodeling and exercise capacity. 
Importantly, there was no additional increase in 6MWD after 
the 6-month follow-up, as already discussed. Nonetheless, 
obtaining similar results from other centers and results from 
randomized trials may further support that patients with PH 
could benefit from PADN.
Clinical end points should be the primary goal of such 
studies,4,18 as reflected in a recent trial.21 However, the rate 
of PAH-related events after medication has not been clearly 
reported. The most recent study21 on the use of macitentan 
in group I PAH patients reported that the 6-month PAH-
related event and all-cause mortality rates were 34.7% 
and 16.6%, respectively, significantly higher than those 
(12.8% and 5.1%, respectively) at 6 months after PADN. 
In this study, the 1-year Kaplan–Meier–estimated PAH-
related event and mortality rates after PADN were 15.0% 
and 12.1%, still lower than those in previous trials, despite 
the enrollment of a high-risk cohort that was nonresponsive 
to numerous pharmacological agents. However, a random-
ized trial will ultimately be required to determine whether 
PADN provides meaningful clinical benefit to patients with 
group I PAH.
The innervation of the pulmonary artery is predominantly 
sympathetic22; the PA receives innervation from the right car-
diac recurrent nerve, with branches forming an adventitial nerve 
plexus.22,23 The innervation starts at the bundles of large nerve 
trunks that diminish in size such that at the level of the arterioles, 
there is only a single fiber,23 a finding that reflects the methodol-
ogy underlying PADN that involves ablation at 3 points around 
the distal main PA level in our consecutive patients.
Since the first report on surgical PA denervation by Juratsch 
et al8 in 1980, PADN was confirmed in our study7 and in the 
study by Rothman et al.20 Given the negative results after renal 
denervation for resistant hypertension, 1 merit of PADN was 
the immediate reduction in PAP after the procedure, which 
was sustained throughout the follow-up period. Furthermore, 
all PAH target drugs were discontinued after PADN because 
no improvement was observed in this patient population, and 
our results showed the net effects of PADN on the end points. 
Unfortunately, given the lack of a control group, any benefit 
observed in this study may be negated in larger randomized 
controlled, adequately powered trials.
Risk models for patients with PAH treated with medi-
cations have been established previously.24–27 A high on-
treatment sPAP,25 elevated RA pressure,25 pericardial 
effusion,26 and resting heart rate cutoffs of 80 to 82 bpm 
for patients with IPAH27 are independently associated 
with increased mortality. Because of the small number 
Figure 3. Kaplan–Meier survival analysis. The 1-year Kaplan–
Meier–estimated rate of pulmonary arterial hypertension (PAH)–
related events was 15.2%. PADN indicates pulmonary artery 
denervation.
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of patients and only 10 PAH-related events in our report, 
the results of the univariable analysis showed that dis-
ease severity predicted the likelihood of increased rate of 
adverse events after PADN.
Limitations
This study was a nonrandomized and open-label study that 
may have a possible bias; the study also lacked a control 
group. Nonetheless, the favorable clinical outcomes after 
PADN are supported by objective improvements in PAPs, 
exercise capacity, and clinical events. Second, the small num-
ber of patients precluded detailed analysis of whether there 
were differential responses to PADN based on the PAH mech-
anism. Finally, all the PADN procedures were performed by 
1 surgeon; nonetheless, our results should be interpreted with 
caution.
Conclusions
This study demonstrated that in a high-risk patient population, 
PADN was safe and effective in reducing PAP and improving 
6MWD and was associated with favorable clinical outcomes 
throughout the 1-year follow-up. Multicenter randomized tri-
als are warranted to determine the use of PADN in patients 
with PAH.
Acknowledgments
We appreciate the assistance of Dr Duan, who worked as the Director 
of the Independent Clinical Event Committee. We also thank Ling 
Lin, Hai-Mei Xue, and Ying-Ying Zhao who collected all of the data 
for the study.
Sources of Funding
This study was funded by a grant from the National Natural Science 
Foundation of China and Jiangsu Provincial Special Program of 
Medical Science (BL2013001), Nanjing, Jiangsu, China.
Disclosures
None.
References
 1. Anderson JR, Nawarskas JJ. Pharmacotherapeutic management of pulmo-
nary arterial hypertension. Cardiol Rev. 2010;18:148–162. doi: 10.1097/
CRD.0b013e3181d4e921.
 2. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi 
A. A meta-analysis of randomized controlled trials in pulmonary arte-
rial hypertension. Eur Heart J. 2009;30:394–403. doi: 10.1093/eurheartj/
ehp022.
 3. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, 
Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin 
L, Barst RJ; Pulmonary Arterial Hypertension and Response to 
Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary ar-
terial hypertension. Circulation. 2009;119:2894–2903. doi: 10.1161/
CIRCULATIONAHA.108.839274.
 4. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè 
N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, 
Tapson VF, Seeger W. End points and clinical trial design in pulmonary 
arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S97–S107. 
doi: 10.1016/j.jacc.2009.04.007.
 5. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel 
PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch 
DB; PACES Study Group. Addition of sildenafil to long-term intravenous 
epoprostenol therapy in patients with pulmonary arterial hypertension: a 
randomized trial. Ann Intern Med. 2008;149:521–530.
 6. Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, 
Ghofrani HA, Sundin DP, Galiè N; Pulmonary Arterial Hypertension and 
Response to Tadalafil (PHIRST) Study Group. Tadalafil monotherapy and 
as add-on to background bosentan in patients with pulmonary arterial 
hypertension. J Heart Lung Transplant. 2011;30:632–643. doi: 10.1016/ 
j.healun.2010.11.009.
 7. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, Stone GW. 
Pulmonary artery denervation to treat pulmonary arterial hyperten-
sion: the single-center, prospective, first-in-man PADN-1 study (first-
in-man pulmonary artery denervation for treatment of pulmonary artery 
hypertension). J Am Coll Cardiol. 2013;62:1092–1100. doi: 10.1016/ 
j.jacc.2013.05.075.
 8. Juratsch CE, Jengo JA, Castagna J, Laks MM. Experimental pulmonary 
hypertension produced by surgical and chemical denervation of the pul-
monary vasculature. Chest. 1980;77:525–530.
 9. Chen SL, Zhang YJ, Zhou L, Xie DJ, Zhang FF, Jia HB, Wong SS, Kwan 
TW. Percutaneous pulmonary artery denervation completely abolishes 
experimental pulmonary arterial hypertension in vivo. EuroIntervention. 
2013;9:269–276. doi: 10.4244/EIJV9I2A43.
 10. Tonelli AR, Mubarak KK, Li N, Carrie R, Alnuaimat H. Effect of bal-
loon inflation volume on pulmonary artery occlusion pressure in patients 
with and without pulmonary hypertension. Chest. 2011;139:115–121. 
doi: 10.1378/chest.10-0981.
 11. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports 
Exerc. 1982;14:377–381.
 12. Tei C, Nishimura RA, Seward JB, Tajik AJ. Noninvasive Doppler-derived 
myocardial performance index: correlation with simultaneous measure-
ments of cardiac catheterization measurements. J Am Soc Echocardiogr. 
1997;10:169–178.
 13. Breda AP, Pereira de Albuquerque AL, Jardim C, Morinaga LK, Suesada 
MM, Fernandes CJ, Dias B, Lourenço RB, Salge JM, Souza R. Skeletal 
muscle abnormalities in pulmonary arterial hypertension. PLoS One. 
2014;9:e114101. doi: 10.1371/journal.pone.0114101.
 14. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de 
Borne P. Increased sympathetic nerve activity in pulmonary artery 
hypertension. Circulation. 2004;110:1308–1312. doi: 10.1161/01.
CIR.0000140724.90898.D3.
 15. Grigioni F, Potena L, Galiè N, Fallani F, Bigliardi M, Coccolo F, Magnani 
G, Manes A, Barbieri A, Fucili A, Magelli C, Branzi A. Prognostic im-
plications of serial assessments of pulmonary hypertension in severe 
chronic heart failure. J Heart Lung Transplant. 2006;25:1241–1246. 
doi: 10.1016/j.healun.2006.06.015.
 16. Hernandez AF, Hammill BG, O’Connor CM, Schulman KA, Curtis 
LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart fail-
ure: findings from the OPTIMIZE-HF (Organized Program to Initiate 
Lifesaving Treatment in Hospitalized Patients with Heart Failure) 
Registry. J Am Coll Cardiol. 2009;53:184–192. doi: 10.1016/ 
j.jacc.2008.09.031.
 17. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats 
TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, 
Yancy CW. 2009 focused update: ACCF/AHA guidelines for the diagnosis 
and management of heart failure in adults: a report of the American College 
of Cardiology Foundation/American Heart Association task force on prac-
tice guidelines: developed in collaboration with the International Society 
for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016. 
doi: 10.1161/CIRCULATIONAHA.109.192064.
 18. Galiè N, Simonneau G, Barst RJ, Badesch D, Rubin L. Clinical wors-
ening in trials of pulmonary arterial hypertension: results and implica-
tions. Curr Opin Pulm Med. 2010;16(suppl 1):S11–S19. doi: 10.1097/01.
mcp.0000370206.61003.7e.
 19. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen 
BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-
Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. 
A controlled trial of renal denervation for resistant hypertension. N Engl J 
Med. 2014;370:1393–1401.
 20. Rothman A, Arnold N, Chang W, Suvarna S, Elliot C, Condliffe R, Kiely 
D, Gunn J, Lawire A. Pulmonary artery denervation reduced pulmo-
nary artery pressure and induces histological changes in an acute por-
cine model of pulmonary hypertension. Circulation Cardiovasc Interv. 
2015;8:e002569.
 21. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, 
Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, 
Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau 
G; SERAPHIN Investigators. Macitentan and morbidity and mortality 
in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–818. 
doi: 10.1056/NEJMoa1213917.
9  Chen et al  Outcomes After PADN for PH
 22. Verity MA, Bevan JA. Fine structural study of the terminal effecror plexus, 
neuromuscular and intermuscular relationships in the pulmonary artery. J 
Anat. 1968;103(pt 1):49–63.
 23. Richardson JB. Nerve supply to the lungs. Am Rev Respir Dis. 
1979;119:785–802.
 24. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman 
AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, 
McGoon MD. Predicting survival in pulmonary arterial hypertension: 
insights from the Registry to Evaluate Early and Long-Term Pulmonary 
Arterial Hypertension Disease Management (REVEAL). Circulation. 
2010;122:164–172. doi: 10.1161/CIRCULATIONAHA.109.898122.
 25. Le Tourneau T, Richardson M, Juthier F, Modine T, Fayad G, Polge AS, 
Ennezat PV, Bauters C, Vincentelli A, Deklunder G. Echocardiography 
predictors and prognostic value of pulmonary artery systolic pressure 
in chronic organic mitral regurgitation. Heart. 2010;96:1311–1317. 
doi: 10.1136/hrt.2009.186486.
 26. Hinderliter AL, Willis PW IV, Long W, Clarke WR, Ralph D, Caldwell EJ, 
Williams W, Ettinger NA, Hill NS, Summer WR, de Biosblanc B, Koch G, 
Li S, Clayton LM, Jöbsis MM, Crow JW. Frequency and prognostic signifi-
cance of pericardial effusion in primary pulmonary hypertension. PPH Study 
Group. Primary pulmonary hypertension. Am J Cardiol. 1999;84:481–484.
 27. Hildenbrand FF, Fauchère I, Huber LC, Keusch S, Speich R, Ulrich S. 
A low resting heart rate at diagnosis predicts favourable long-term out-
come in pulmonary arterial and chronic thromboembolic pulmonary hy-
pertension. A prospective observational study. Respir Res. 2012;13:76. 
doi: 10.1186/1465-9921-13-76.
